Introduction {#S0001}
============

Low back pain (LBP) affects individuals of all ages and is considered to cause more years lived with disability than any other health condition worldwide.[@CIT0001],[@CIT0002] The contribution of LBP to disability is likely to increase in the context of the aging population.[@CIT0001] While the vast majority of LBP episodes resolve within 2--4 weeks, a third of patients will experience recurrent episodes within 1 year or chronic LBP, the prevalence of which is increasing.[@CIT0003]--[@CIT0005] Unfortunately for this population, coping with back pain might be a lifetime challenge[@CIT0006] and these recurrent episodes and chronic cases are responsible for most of the health expenses related to LBP.[@CIT0007] In addition, the intensity of LBP can vary in individuals over time without any active treatment.

The number of therapies available to manage chronic or recurrent LBP (crLBP) is broad, ranging from surgery to pharmacotherapy and to non-pharmacological treatments.[@CIT0008],[@CIT0009] The effectiveness and safety of pharmacotherapy has, however, been challenged, including the use of acetaminophen, NSAIDs, anticonvulsants (eg, gabapentin, pregabalin), and opioids.[@CIT0010]--[@CIT0014] On the other hand, evidence is emerging regarding the benefits of some non-pharmacological or complementary medicine (CM) treatments to improve crLBP outcomes. CM is defined as a group of diverse medical and health-care systems, practices, and products that are not generally considered part of conventional medicine.[@CIT0015]

Indeed, recent studies have shown beneficial effects of yoga,[@CIT0016] acupuncture,[@CIT0017] osteopathic treatment,[@CIT0018] hypnosis,[@CIT0019] Taï chi,[@CIT0020] therapeutic massage,[@CIT0021] and exercise therapy[@CIT0022] for crLBP.

Given these recent findings, in 2017, the American College of Physicians shifted its guidelines for crLBP management by recommending as first-line options non-pharmacological therapies, including exercise (pain and function: small effect, moderate-quality evidence), acupuncture (pain and function: moderate effect, moderate-quality evidence), mindfulness-based stress reduction (pain and function: small effect, moderate-quality evidence), tai chi (pain: moderate effect, low-quality evidence; function: small effect, low-quality evidence) and yoga (pain and function: small to moderate effect, low-quality evidence), and recommending pharmacological treatment, like NSAIDs (pain: small effect, moderate-quality evidence; function: small effect, low-quality evidence) only following an inadequate response to first-line non-pharmacological interventions[@CIT0023] However, this recommendation is based on moderate-quality evidence and most of the data on these therapies have only shown short-term effects.

CrLBP is a frequent reason for patients to seek physiotherapy, exercise therapy, and CM.[@CIT0024],[@CIT0025] In Switzerland, the lifetime prevalence of CM use for crLBP among patients consulting at a tertiary pain center was 77.3%,[@CIT0026] with osteopathic treatment, therapeutic massage, and acupuncture being the most frequently used therapies. Acupuncture, homeopathy, herbal medicine, hypnosis, Chinese herbs, and anthroposophic medicine are reimbursed by mandatory basic health insurance in Switzerland if provided by a physician. In addition, there are four main groups of manipulative therapies in Switzerland, provided by four different professions with specific training: manual medicine provided by trained physicians, chiropractic by chiropractors, physiotherapy by physiotherapists, and osteopathy by osteopaths. Manual therapy and chiropractic are reimbursed by mandatory basic health insurance, as well as physiotherapy if prescribed by a physician. Osteopathy and all other CM therapies require supplementary insurance in order to be covered (see [Table 3](#T0003){ref-type="table"}, second column for insurance coverage).[@CIT0027] In 2012, about 60%[@CIT0028] of the Swiss population had supplementary health insurance for CM. Many different supplementary health insurance schemes are available in Switzerland, and the offer is heterogeneous across health insurance companies. Since CM that is not covered by basic health insurance does not require a medical prescription, access to most forms of CM is self-prescribed and consumption of CM services is not available in routine statistics. The concomitant use of CM and conventional medicine is frequent in Switzerland[@CIT0029] and in the US, especially for LBP.[@CIT0025],[@CIT0026] A recent meta-analysis revealed a 33% disclosure rate for biologically based CM[@CIT0030] Reasons for non-disclosure often included the patients' fear to be disapproved by their physician, or the fact that the physician did not ask. Reasons for disclosure often included the fact that the physician asked. The authors of this review concluded that disclosure of CM use to physicians should be encouraged to improve the safety and effectiveness of patient care. The disclosure rate of CM use for crLBP has been estimated at a Pain center (47%),[@CIT0026] but it is not known in private practice in Switzerland.Table 1Patients' socio-demographic characteristics (N=499)Variablen (%)Age, mean (SD)59.6 (15.3)**Sex (n=496/499)**\
 Male\
 Female\
162 (32.7)\
334 (67.3)**Origin (n=492/499)**\
 Swiss\
 Other\
426 (86.6)\
66 (13.4)**Educational level (n=492/499)**\
 Basic (until college)\
 Apprenticeship\
 University, professional diploma/high school\
90 (18.3)\
180 (36.6)\
222 (45.1)**Living status (n=496/499)**\
 Single\
 Single with children\
 In a relationship with children\
 In a relationship without children\
 Other\
139 (28.0)\
31 (6.3)\
120 (24.2)\
179 (36.1)\
27 (5.4)**Current smoking (n=499/499)** Yes116 (23.2) No383 (76.8)**Health coverage of CM (n=489/499)**\
 Yes\
 No\
 Unknown\
326 (66.7)\
123 (25.2)\
40 (8.2)[^1][^2] Table 2Participants' pain characteristics (N=499)Pain characteristicsn (%)**Pain frequency in the past 6 months (n=484/499)** Every day or almost every day243 (50.2) Every other day89 (18.4) Less than every other day114 (23.6) No pain in the past 6 months38 (7.9)**Duration of pain^a^ (n=467/470)** \<1 year61 (13.1) ≥1 to \<5 years116 (24.8) ≥5 years290 (62.1)**Pain intensity in the past 6 months^a,b^ (n=450/470)** Mild (1--3)82 (18.2) Moderate (4--6)235 (52.2) Severe (7--10)133 (29.6)**RTF impact classification score^a,c^ (n=453/470)** Mild (8--27)94 (20.8) Moderate (28--34)222 (49.0) Severe (35--50)137 (30.2)[^3][^4][^5][^6] Table 3Lifetime use of assessed therapies and their perceived usefulness in crLBP management (minimal number of responses for therapy, n=485)TherapyInsurance coverageParticipants (n=499)ICCPerceived usefulnessICCPCPs (n=45)UseAgreeing about usefulnessn (%)Mean (SD)PhysiotherapyBasic405 (81.8)0.1396.0 (2.6)0.00144 (97.8)Osteopathic treatment^a^CMI312 (63.4)0.0686.7 (2.5)0.08542 (93.3)Exercise therapyBasic261 (53.4)0.0126.0 (2.7)0.100MissingOpioidsBasic244 (52.5)0.0746.3 (2.6)\<0.00131 (68.9)Therapeutic massage^a^CMI249 (50.8)0.0595.9 (2.5)\<0.00137 (82.2)Spinal/nerve blockBasic163 (33.6)0.0315.2 (3.5)\<0.001MissingAcupuncture^a^Basic155 (31.3)0.0235.1 (3.0)\<0.00133 (73.3)Chiropractic treatmentBasic148 (30.1)0.0025.5 (2.7)0.00431 (68.9)Traditional healing^a^CMI143 (28.9)0.0545.5 (2.6)0.05923 (51.1)Manual therapyBasic110 (22.7)0.1326.2 (2.6)\<0.00138 (84.4)Homeopathy^a^Basic or CMI107 (22.0)0.1104.4 (2.5)0.29415 (33.3)Reflexology^b^CMI74 (15.0)0.0605.0 (2.4)0.22922 (48.9)Aromatherapy^a^CMI73 (14.8)0.0355.1 (2.7)0.2653 (6.7)Yoga^b^CMI70 (14.2)0.1025.3 (2.8)\<0.00140 (88.9)Magnetism^a^CMI70 (14.1)\<0.0015.1 (2.8)0.06129 (64.5)Kinesiology^a^CMI63 (12.8)\<0.0015.3 (2.8)0.04212 (26.3)Meditation^a^--56 (11.4)\<0.0015.2 (2.4)\<0.00138 (86.4)Herbal medicine^a^Basic or CMI49 (10.0)0.1274.8 (2.5)0.11920 (44.5)Psychological adviceBasic or CMI49 (10.1)0.0635.5(2.9)\<0.001MissingReiki^a^CMI44 (8.9)\<0.0015 (2.8)0.3629 (20.0)Low back surgical interventionBasic61 (12.3)0.1207.1 (3.1)\<0.001MissingSophrology^a^CMI37 (7.4)0.0474.9 (2.1)\<0.00135 (78.0)Shiatsu^a^CMI31 (6.3)0.1415.4 (2.6)0.30724 (53.3)Tai chi and/or qi gong^a^CMI26 (5.3)0.0875.5 (2.9)\<0.00132 (71.1)Hypnosis^a^Basic or CMI24 (4.8)0.0434.6 (2.4)0.00035 (77.8)Ayurvedic medicine^a^CMI19 (3.8)\<0.0014.1 (2.5)0.46811 (24.4)Chinese herbs^a^Basic18 (3.6)\<0.0013.4 (3.0)0.9029 (20.0)Art therapy^a^CMI7 (1.4)\<0.0016.9 (2.7)13 (28.9)Anthroposophic medicine^a^Basic or CMI2 (0.4)\<0.0010 (0.0)5 (11.1)[^7][^8][^9]

To the best of our knowledge, no population-based studies have specifically examined the use of a diversity of treatments for the management of crLBP in primary care. Thus, we aimed to provide insights into the use of a wide range of treatments for crLBP, including a detailed list of CM therapies, independently of whether they had been prescribed by a physician and the patient had been reimbursed. Our main objective was to assess the prevalence of use of the most common crLBP treatments by primary care patients and to describe perceived usefulness of both patients and their primary care physicians (PCPs) in western Switzerland. Furthermore, we explored associated variables with therapies used for crLBP. Our secondary objective was to describe PCP-patient communication about CM use for crLBP management.

Methods {#S0002}
=======

Study design {#S0002-S2001}
------------

This cross-sectional study was conducted in a series of primary care practices of the western French-speaking part of Switzerland from November 1, 2015, to May 31, 2016. PCPs recruited consecutive consenting patients with crLBP during regular medical visits ([Figure 1](#F0001){ref-type="fig"}).Figure 1Flow chart of study participants.**Abbreviation:** PCP, primary care physicians.

Setting and participants {#S0002-S2002}
------------------------

PCPs were recruited from small or large practices in both urban and rural settings, in the different regions of the French part of Switzerland. The enrolled physicians completed and returned the paper questionnaire, which was an inclusion criterion for enrolling participants in the study. Eligible participants had crLBP, were 18 years of age or more, and were able to read and understand French. CrLBP was defined as pain lasting or recurring for 3 months or more[@CIT0031] and recurring LBP was defined as ≥2 episodes of LBP during the previous year, with a significant impact on the patient's daily life.

During the study period, the PCP screened each visiting patient for the presence of crLBP, regardless of the reason for consultation, and handed out the questionnaire to 30 consecutive eligible patients. Patients were asked to complete the questionnaire at home and to return it in the prestamped envelope to the research team. Patients were entirely anonymous to the research team. Participation to the survey was voluntary. For each physician, the study ended after they had distributed 30 patient questionnaires or after 4 months following the recruitment of the first patient. As the questionnaires were anonymous, no informed consent had to be signed. By filling out the survey, participants gave implied consent. The study protocol and the questionnaires were approved by the committee on medical research ethics of the Canton of Vaud (ID Nb. 303/15).

Sample size calculation {#S0002-S2003}
-----------------------

For the sample size estimation, we relied on the 59% prevalence of CM use for cLBP according to US data.[@CIT0025] Given the cluster (physician) design of the study, we used an intracluster correlation of 0.03. In order to get a 5% width CI around the estimate, the number of patients needed amounted to 480.

Development of the questionnaire {#S0002-S2004}
--------------------------------

The patient and the PCP questionnaires were based on previously published instruments.[@CIT0026],[@CIT0032],[@CIT0033] Questionnaires are provided in the [supplementary material 1](https://www.dovepress.com/get_supplementary_file.php?f=200375.pdf) and [2](https://www.dovepress.com/get_supplementary_file.php?f=200375.pdf). Both questionnaires were cognitively tested. This test aimed to assess how respondents understood the intent and meaning of survey items and whether their answers agreed with the interpretations of the researchers. A convenience sample of 10 volunteer crLBP patients and 10 healthy volunteers from the general population with a wide range of sociodemographic features took part in the cognitive interviews. The 10 volunteer patients with crLBP did not take part in the study. Amendments were made to the questionnaire to improve comprehension of the survey items. We evaluated the stability of the questionnaire by means of a test--retest reliability procedure. Seven patients were asked if they would agree to provide their postal address in order to send them the same questionnaire 2 weeks after we had received their first-completed questionnaire. Although the seven patients completed the retest, the number of participants was too low to perform a concordance or reliability measurement by item. However, we observed a mean agreement of 87% between the first and the second questionnaire.

Variables {#S0002-S2005}
---------

We developed two questionnaires. The patients questionnaire that was divided into several sections, which explored the following: 1) sociodemographic and lifestyle data, 2) duration and burden of LBP, 3) pain interference with normal activities and functional status, and 4) patients' lifetime use and perception of usefulness of 30 therapies specifically for crLBP, 21 of which were CM therapies. Therapies chosen for the questionnaire were based on the potentially most used therapies according to different factors: prevalence of use, reimbursement by the Swiss healthcare system or scientific evidence. All therapies considered as CM in the present study are indicated with a superscript letter in [Table 3](#T0003){ref-type="table"}. As recommended in the report of the National Institutes of Health task force on research standards for crLBP,[@CIT0034] we used the research task force impact classification scoring tool to determine the impact of crLBP on respondents' daily life. PROMIS (Patient Reported Outcomes Measurement Information System) scores for pain intensity, physical function, and pain interference[@CIT0034],[@CIT0035] were part of this measurement tool. Current smoking was assessed with the question: "Do you currently smoke, even occasionally?" (answer: yes/no).[@CIT0036],[@CIT0037] The PCP questionnaire was divided into 4 sections exploring: 1) socio-demographic data, 2) PCPs' perception of usefulness of 25 therapies specifically for crLBP, 23 of which were CM therapies, and their reported prescribing behavior, 3) PCPs' perceived usefulness of CM in general and of specific CM treatments and their recommendations, and 4) PCP's attitude towards use of CM.

Statistical analysis {#S0002-S2006}
--------------------

Statistical analyses were performed using R version 3.5.0. We considered that missing values occurred completely at random and proceeded to complete cases analyses. Results were expressed as means (SD) or as percentages. Intraclass correlation coefficients (ICC) were calculated for [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"} in order to quantify the cluster effect. ICC are estimated using mixed models. ICC is defined as the ratio of between-cluster variance to total variance. The variances are estimated using regression model with random intercept and no other predictors. Multivariate analysis was performed using logistic regression and results were expressed as OR and 95% CI. We performed multivariate analyses for the therapies used by at least 20% of participants. The response variable was the use or not of the therapy and the explicative variables were patients' age, gender, education, smoking habits, pain duration, CM insurance coverage, the PCPs' gender, age, and training in CM. These explicative variables were selected because they were often associated with therapy use in other studies.[@CIT0025],[@CIT0026],[@CIT0038] Since the ICC were not negligible in univariate analyses, a random effect was considered to take account of the cluster design.[@CIT0039]Table 4Multivariate associations of lifetime use of therapies by patients living with chronic low back pain, for therapies used by at least 20% of participants, according to sociodemographic variables, pain duration, insurance coverage, and PCP characteristicsPhysiotherapyOsteopathic treatmentExercise therapyOpioidsTherapeutic massageSpinal/nerve blockAcupunctureChiropractic treatmentTraditional healingManual therapyHomeopathyNon-users/users/ICC332/75/0.11264/138/\<0.001216/187/\<0.001208/180/0.02204/200/0.06136/264/\<0.001136/270/\<0.001123/279/\<0.001113/291/\<0.00191/305/0.1196/302/0.04OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)Age category (years) 18--49refrefrefrefrefrefrefrefrefrefref 50--640.8 (0.4--1.8)0.7 (0.4--1.4)0.7 (0.4--1.3)0.8 (0.4--1.4)1.2 (0.7--2.1)1.1 (0.6--2.0)1.7 (1.0--3.1)1.4 (0.8--2.6)0.7 (0.4--1.4)1.1 (0.6--2.2)1.3 (0.7--2.5) 65--740.8 (0.4--1.8)0.8 (0.4--1.5)0.8 (0.4--1.4)0.9 (0.5--1.6)0.7 (0.4--1.2)1.2 (0.7--2.2)1.2 (0.7--2.3)1.1 (0.6--2.0)0.7 (0.4--1.3)0.8 (0.4--1.7)1.4 (0.7--2.7) ≥751.1 (0.5--2.9)0.3 (0.1--0.5)\*\*\*0.6 (0.3--1.2)1.1 (0.5--2.1)1.0 (0.5--1.9)1.9 (1.0--3.8)0.9 (0.4--1.9)0.5 (0.2--1.1)0.2 (0.1--0.6)\*\*0.4 (0.2--1.2)0.4 (0.1--1.1)Gender Male^a^/female1.0 (0.5--1.8)1.9 (1.2--3.0)\*1.0 (0.6--1.5)1.1 (0.7--1.8)1.1 (0.7--1.8)1.2 (0.7--1.9)1.4 (0.8--2.2)0.6 (0.4--1.0)0.7 (0.4--1.1)1.3 (0.7--2.3)0.8 (0.5--1.4)Education Basic (until college)refrefrefrefrefrefrefrefrefrefref Apprenticeship1.0 (0.5--2.2)2.2 (1.2--4.2)\*0.5 (0.3--0.9)\*0.7 (0.4--1.3)0.8 (0.4--1.5)1.0 (0.5--1.8)1.0 (0.5--1.9)0.6 (0.3--1.2)1.6 (0.8--3.1)1.9 (0.9--4.3)1.1 (0.5--2.2) High school, university1.4 (0.7--3.1)2.3 (1.3--4.1)\*\*0.8 (0.5--1.5)0.7 (0.4--1.2)0.9 (0.5--1.6)0.8 (0.5--1.5)0.9 (0.5--1.6)0.7 (0.3--1.2)0.7 (0.4--1.4)1.6 (0.7--3.5)1.1 (0.5--2.2)Smoking habits Yes/no^a^1.1 (0.5--2.1)0.6 (0.4--1.1)0.5 (0.3--0.9)\*\*1.8 (1.1--3.1)\*1.4 (0.8--2.3)1.0 (0.6--1.6)1.5 (0.9--2.5)0.6 (0.3--1.1)1.0 (0.5--1.7)1.4 (0.7--2.6)1.0 (0.5--1.8)Pain duration ≤5 yearsrefrefrefrefrefrefrefrefrefrefref \>5 years2.3 (1.3--4.1)\*\*0.9 (0.6--1.4)2.1 (1.3--3.2)\*\*1.4 (0.9--2.2)1.5 (1.0--2.4)1.6 (1.0--2.6)\*1.4 (0.9--2.3)1.9 (1.2--3.2)\*\*2.0 (1.2--3.4)\*\*1.8 (1.0--3.3)\*\*1.2 (0.7--2.0)CM insurance coverage Yes/no^a^0.9 (0.5--1.7)1.8 (1.1--3.0)\*1.1 (0.7--1.7)0.7 (0.4--1.2)0.7 (0.4--1.1)0.9 (0.5--1.4)1.4 (0.9--2.3)2.5 (1.4--4.5)\*\*\*1.6 (0.9--2.8)1.4 (0.8--2.6)1.3 (0.8--2.4)PCP gender Female/male^a^0.7 (0.3--1.5)0.9 (0.5--1.5)0.7 (0.4--1.1)0.9 (0.5--1.5)0.7 (0.4--1.2)0.7 (0.4--1.2)1.0 (0.6--1.6)0.8 (0.5--1.3)1.0 (0.6--1.8)1.5 (0.7--3.1)1.3 (0.7--2.5)PCP age (years) ≤35refrefrefrefrefrefrefrefrefrefref 36--450.6 (0.1--3.6)1.0 (0.3--2.9)0.9 (0.3--2.4)2.4 (0.7--7.9)0.6 (0.1--2.5)0.8 (0.3--2.4)0.7 (0.2--1.9)0.6 (0.2--1.6)0.7 (0.3--2.1)0.3 (0.1--1.9)0.3 (0.1--1.2) 46--551.2 (0.2--8.1)1.3 (0.4--4.1)0.7 (0.3--1.9)2.1 (0.6--6.8)0.9 (0.2--3.7)0.8 (0.3--2.4)1.3 (0.4--3.5)0.6 (0.2--1.6)0.7 (0.2--1.9)0.5 (0.1--2.9)0.5 (0.1--1.7) ≥560.8 (0.1--5.4)1.0 (0.3--2.9)0.9 (0.3--2.4)1.7 (0.5--5.6)0.8 (0.2--3.4)0.9 (0.3--2.6)0.7 (0.2--2.0)0.4 (0.1--1.3)0.5 (0.2--1.5)0.4 (0.1--2.3)0.4 (0.1--1.6)PCP education in CM^b^ Yes/No*^a^*0.6 (0.3--1.3)1.1 (0.7--1.8)1.1 (0.7--1.8)0.5 (0.3--0.9)\*0.8 (0.4--1.4)1.0 (0.6--1.5)0.7 (0.4--1.1)0.9 (0.5--1.5)1.2 (0.7--2.1)1.6 (0.8--3.5)1.4 (0.8--2.6)[^10][^11]

Results {#S0003}
=======

Response rate {#S0003-S2001}
-------------

Of 149 PCPs contacted, 60 agreed to participate and 45 eventually did ([Figure 1](#F0001){ref-type="fig"}). A total of 514 completed patient questionnaires were returned, 15 of which could not be included because the two PCPs associated with the patients did not return their own questionnaire. Thus, the patient response rate was 37% (499 of 1350). Selected sociodemographic characteristics are summarized in [Table 1](#T0001){ref-type="table"}. Over half of the participants (n=272, 55%) were unemployed, most of these being retired (n=205, 75%).

LBP characteristics {#S0003-S2002}
-------------------

Pain characteristics are presented in [Table 2](#T0002){ref-type="table"}. For most participants, crLBP had been an ongoing problem for \>5 years. Almost a third of the participants experienced severe LBP and half experienced moderate LBP in the 6 months before completing the questionnaire. Half of the participants had experienced LBP every day or nearly every day during the 6 months before completing the survey. The impact score of LBP on daily living was rated as moderate or severe by 79.2% of study participants.

Therapies used to manage crLBP {#S0003-S2003}
------------------------------

The top 5 therapies used by patients for crLBP during their lifetime were physiotherapy, followed by osteopathic treatment, exercise therapy, opioids and therapeutic massage ([Table 3](#T0003){ref-type="table"}). Overall, the mean number of different therapies used by each participant was 6.5 (SD=3.9). [Table 3](#T0003){ref-type="table"} shows which treatments are reimbursed by basic or CM health insurance in Switzerland. The therapies most often used by patients are not always reimbursed by basic health insurance coverage. Among the top 5 therapies used to relieve crLBP during a patient's lifetime, no medical prescription is required for osteopathic treatment and therapeutic massage. Among the therapies used by at least 20% of participants (ie, 11 therapies), the five therapies rated by the patients (who used those therapies) as being most helpful for this condition were osteopathic treatment, opioids, manual therapy, physiotherapy, and exercise therapy. Among these 11 frequently used therapies, only homeopathy received a mean perceived usefulness score under 5 points (on a 0--10 visual analog scale) according to the patients. Among 25 therapies, the five therapies rated as being most useful according to PCPs were physiotherapy, osteopathic treatment, yoga, meditation, and manual therapy. Regarding the group of therapies considered as CM specifically, 86.6% of the participants had used at least one of them to manage their crLBP during their lifetime, with a mean of 3.3 (SD=2.9) CM therapies used per participant. In the previous 12 months, 61.1% of participants reported any CM use for crLBP.

Multivariate analysis {#S0003-S2004}
---------------------

In the continuity of the primary objective, we identified the factors associated with therapies used for crLBP by at least 20% of the participants during their lifetime. [Table 4](#T0004){ref-type="table"} shows the multivariate analysis of participants' consumption patterns for those therapies, adjusted for patients' age, gender, education, current smoking, pain duration, and CM insurance coverage, as well as for PCPs gender, age, and training in CM. Except for osteopathic treatment, which was used significantly more often by women, patient gender was not associated with the consumption of any therapy. Older age of patients (≥75 years) was negatively associated with the use of osteopathic treatment and traditional healing. A higher education was significantly associated with increased use of osteopathic treatment for crLBP. Current smoking was associated with significantly greater odds of having used opioids and significantly lower odds of having followed exercise therapy for crLBP. Respondents having experienced crLBP for \>5 years were more likely to have resorted to physiotherapy, exercise therapy, spinal/nerve block, chiropractic treatment, traditional healing, and manual therapy than were respondents having experienced crLBP for \<5 years. Respondents having CM insurance coverage were more likely to have used osteopathic treatment and chiropractic treatment for crLBP. Neither the PCPs' age nor their gender was significantly associated with patients' lifetime use of any therapy. Participants visiting a PCP who had training in CM were significantly less likely to have resorted to opioids during their lifetime to manage crLBP.

Patient-PCP communication {#S0003-S2005}
-------------------------

Regarding communication, 46.1% of the participants reported that their PCP did not enquire about their CM use. Among patients using CM (n=465), 64.7% spontaneously informed their PCP about their CM use. Among all patients, 42.7% reported that the PCP advised CM as a treatment option for crLBP. Most patients (80.4%) would be likely or very likely to try CM if their PCP offered such a treatment option.

Discussion {#S0004}
==========

Patients with crLBP who visited their PCPs used a wide range of therapies, not always covered by basic health insurance, to manage their condition. The top five therapies used for crLBP during a patient's lifetime were physiotherapy, osteopathic treatment, exercise therapy, opioids, and therapeutic massage. Study participants had used on average 6.5 therapies to manage their crLBP during their life. The use of physiotherapy was significantly associated with longer pain duration; osteopathic treatment was associated with age under 75 years, female gender, higher education, and CM insurance coverage. Exercise therapy was associated with non-smoking and longer pain duration. The PCPs' age and gender were not associated with the use of specific crLBP treatments. Patients of PCPs who were trained in CM were significantly less likely to have used opioids for crLBP. Regarding communication, about a half of participants reported that their PCP did not enquire about their CM use.

It is difficult to find reliable comparative figures of crLBP treatment use. First, there is a paucity of studies on treatment use that includes both conventional and CM for crLBP. Second, existing estimates vary greatly, depending on clinical setting, period of observation, and CM definition. Osteopathic treatment and therapeutic massage were also among the most commonly used CM in another study in the same city and in an integrative review involving several countries (Australia, Belgium, Canada, Denmark, Germany, UK, and USA).[@CIT0026],[@CIT0040] Lifetime CM use for crLBP was higher in our study (86.6%) than in a study conducted in a tertiary spine orthopedic clinic in Hong Kong (72.3%).[@CIT0041] We also found a higher occurrence of CM use than that found in a pain center in Switzerland (77.3%).[@CIT0026] Our observation that those with crLBP often seek several different treatment options is consistent with the literature.[@CIT0026],[@CIT0040],[@CIT0042],[@CIT0043] Patients and their PCPs had different opinions when rating the usefulness of opioids: patients ranked opioids in second rank (among 11), while their PCPs ranked opioids after the tenth position (among 25 therapies).

Although previous studies reported that female gender, younger age, and higher education were associated with the use of CM therapies,[@CIT0025],[@CIT0044] among the therapies used by \>20% of participants, these three predictors were associated only with osteopathic treatment.

We observed that the lack of coverage of some therapies by the mandatory basic health insurance in Switzerland did not prevent participants from using them. Indeed, some therapies excluded from basic health insurance coverage are among the most used, for example, osteopathic therapy and therapeutic massage. This might suggest that patients are satisfied with these therapies and willing to access them by signing up for supplemental CM insurance coverage or by paying out of pocket. Another explanation could be that having a supplemental insurance coverage for CM therapies could also be a reason why patients resort to CM in first place. Participants with CM insurance coverage were more likely to use chiropractic and osteopathic therapies, which seems surprising because chiropractic treatment is reimbursed by mandatory basic health insurance. One explanation is that patients who underwent osteopathic treatment might also have turned to chiropractic because it is covered by the basic health insurance scheme. However, the temporal sequence of the use of various treatments is not known in the present study.

Regarding PCP prescription practices in individuals presenting with crLBP, previous studies found that the gender of the treating practitioner influenced pain management practices for the treatment of back pain, which does not seem to be the case in our study.[@CIT0045],[@CIT0046] However, the link between PCPs' age and gender and their referral patterns is not always clear in the literature.[@CIT0038],[@CIT0047] In our study, half of the participants indicated that their PCP inquired about CM use, whereas two-thirds of CM users told their PCP about it, which is consistent with previous findings in Switzerland.[@CIT0026] In the Hong Kong study, only one-third of CM users informed their PCPs of such use[@CIT0041] and the same proportion was obtained in the meta-analysis of disclosure rate for biologically-based CM.[@CIT0030] However, this meta-analysis was not focused on crLBP and included a large variety of populations and indications.

In primary care, the patient--PCP partnership and communication are of prime importance in the management of crLBP.[@CIT0048]--[@CIT0050] An effective partnership between patients and PCPs may improve patients' self-ability to manage their pain and could improve patients' health outcomes particularly with the growing acceptation of the concept of patient-centered care in health-care services.[@CIT0050],[@CIT0051] Studies on nondisclosure of CM use consistently mention three main reasons for patients not informing their PCP:[@CIT0052] fear of a negative reaction from the PCP, the view that the PCP does not need to know about patient CM use and does not know much about CM, and the PCP not asking about CM use.[@CIT0030] PCPs should address the question of CM use with their patients more systematically.[@CIT0023] Physicians specialized in integrative and complementary medicine could help inform and guide PCPs and patients with crLBP about the most effective CM treatment options, their potential interactions with conventional therapies, and their side effects. PCPs should open the dialogue with their patients to inform them about effective care options and to establish together shared decision making about crLBP management.

In practice, crLBP patients use a wide range of treatments to manage their condition. Although the high frequency of use and perceived benefit of osteopathic therapy and therapeutic massage seem to be in accordance with rising evidence about the benefit of these therapies in the context of LBP,[@CIT0053],[@CIT0054] our results underline the fact that use of care is not systematically in accordance with the best currently available evidence. Indeed, therapies lacking evidence of effectiveness for crLBP may be overused, such as homeopathy or the frequent use of opioids to treat severe forms of crLBP, despite recent data showing no additional benefit of opioids relative to non-opioid medication.[@CIT0011] Conversely, treatment options may be underused, such as acupuncture, yoga and mindfulness-based stress reduction, as recent data showed a small to moderate effect, with yoga having the lowest quality of evidence.[@CIT0016],[@CIT0023] The guidelines of the American College of Physicians,[@CIT0023] which have provided a recent assessment of effective noninvasive treatments for crLBP (involving both CM and conventional therapies) could be an important tool in improving PCPs' knowledge about effective treatments.

Among the limitations of our study, the use of crLBP-related care during a lifetime is prone to recall bias. Patients with crLBP may have preferentially indicated treatments used to alleviate acute episodes of LBP (in particular self-prescribed therapies). In addition, patients actively involved in their crLBP management may have participated more readily than less concerned patients. This potential selection bias might have led to an overestimation of the total number of therapies used. The high proportion of CM options in the questionnaire could also have led to an overestimation of CM use in comparison with conventional treatments (by drawing the patients' attention to their past CM use). Because the participation rate was limited (33%), and the study did not have any comparison data about nonparticipants, the results of this study might not be generalizable. Despite the adjustment for education level and CM insurance coverage in multivariate analyses, we cannot exclude residual confounding by the financial situation of patients.[@CIT0055] We did not inquire about some pain medications, like the use of acetaminophen or NSAIDs. Such medication being the most prescribed and over-the-counter therapy used overall,[@CIT0056] we did not think that it was relevant to assess its lifetime use, which would certainly reach 100%. However, it could have influenced the ranking of our results concerning the most often used therapies. Our study focused on the prevalence of lifetime use of crLBP treatments and not the therapies used during the previous year only; such a measurement would have shown fewer treatment users. Neither did we ask questions about the frequency of use of each therapy. Another limitation is the lack of information about the exact circumstances in which patients used the mentioned therapies, notably how the LBP episodes were treated. The comparison between the perceptions of PCPs and patients regarding usefulness should be interpreted with great caution because the denominators differed (patients only rated the usefulness of therapies they had used, while physicians rated the usefulness of 25 therapies).

The study strengths include the use of a detailed and relatively comprehensive list of various treatment options, including crLBP treatments requiring no medical prescription, that is, data not available in routine statistics. In addition, we collected data about both the patients and their PCPs. Moreover, the choice of a private-practice-based study design is appropriate because, according to the literature, exclusive CM use for back pain is rare and those who experience back pain use CM alongside conventional medical therapies.[@CIT0040]

Conclusion {#S0005}
==========

Patients visiting their PCP used a wide range of treatments, including conventional and CM therapies for crLBP, and almost half of them did not have the opportunity to discuss these options with their PCP. This study did not reveal an obvious pattern between treatment use and factors such as age, education level and gender of participants. Equipped with this information, PCPs should routinely inquire their patients about their treatment use for their crLBP, including CM.
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Abbreviation list {#S0006}
=================

CM, complementary medicine; CrLBP, chronic or recurrent low back pain; ICC, intraclass correlation coefficient; LBP, low back pain; PCP, primary care physician.
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[^1]: **Notes:** Results are expressed as number of participants (percentage) except where otherwise indicated. Since the participants filled in the paper questionnaires at home, some answers were not completed by all of them and had to be omitted. Therefore, the total n for each question varies. The number and percentage of missing answers for each question does not exceed n=10/499, that is 2.0%.

[^2]: **Abbreviation:** CM, complementary medicine.

[^3]: **Notes:** Results are expressed as number of participants (percentage).

[^4]: ^a^Among the 499 study participants, 29 "without any pain currently" were excluded from these subgroups. Since the participants filled in the paper questionnaires at home, some answers were not completed by all of them and had to be omitted. Therefore, the total n for each question varies. The number and percentage of missing answers for each question does not exceed n=20/470, that is 4.3%.

[^5]: ^b^Pain intensity was calculated on a 0--10 visual analog pain scale.

[^6]: ^c^The research task force (RTF) impact classification score ranges from 8 (least impact) to 50 (greatest impact).

[^7]: **Notes:** --, no insurance coverage. ^a^Indicates therapies considered to be complementary medicine in the present study.

[^8]: For each treatment, data shown include the proportion of participants having used it in their lifetime (column 3), the perceived usefulness rated on a 0--10 visual analog pain scale (0 being useless and 10 being extremely useful, column 5), and the proportion of PCPs who agree or strongly agree with its usefulness (column 7). For clarity, the number of missing answers are not given (but available on request).

[^9]: **Abbreviations:** crLBP, chronic low back pain; PCP, primary care physician; basic, mandatory basic health insurance; CMI, complementary medicine health insurance if provided by an affiliated therapist; ICC, intraclass correlation coefficient.

[^10]: **Notes:** Missing data were managed through complete cases analysis for each therapy. The letter a indicates the reference category for the logistic regression analysis. ^a^Reference group; ^b^PCP training in another CM and/or in manual therapy. \**P*\>0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.

[^11]: **Abbreviations:** CM, complementary medicine; ICC, intraclass correlation coefficient; PCP, primary care physician.
